Prevention and treatment of osteoporosis in inflammatory bowel disease.
The following are guidelines for evaluation and consideration for treatment of patients with inflammatory bone disease (IBD) after bone mineral density (BMD) measurements. The Crohn's & Colitis Foundation of America (CCFA) has indicated that its recommendations are intended to serve as reference points for clinical decision-making, not as rigid standards, limits, or rules. They should not be interpreted as quality standards.
Lichtenstein
Gary R
GR
University of Pennsylvania School of Medicine, Hospital of the University of Pennsylvania, Gastroenterology Division, Department of Medicine, Philadelphia, PA 19104-4283, USA. grl@uphs.upenn.edu
Sands
Bruce E
BE
Pazianas
Michael
M
D015502:Absorptiometry, Photon; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000175:diagnosis; D016723:Bone Remodeling / Q000502:physiology; D002136:Calcium, Dietary / Q000627:therapeutic use; D005598:Fractures, Spontaneous / Q000209:etiology; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D010024:Osteoporosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D012307:Risk Factors; D014807:Vitamin D / Q000627:therapeutic use
D050071:Bone Density Conservation Agents; D002136:Calcium, Dietary; D005938:Glucocorticoids; D014807:Vitamin D